Elena Piskounova
University of Texas Southwestern Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Elena Piskounova.
Cancer Cell | 2012
Jeffrey A. Magee; Elena Piskounova; Sean J. Morrison
The differentiation of tumorigenic cancer stem cells into nontumorigenic cancer cells confers heterogeneity to some cancers beyond that explained by clonal evolution or environmental differences. In such cancers, functional differences between tumorigenic and nontumorigenic cells influence response to therapy and prognosis. However, it remains uncertain whether the model applies to many, or few, cancers due to questions about the robustness of cancer stem cell markers and the extent to which existing assays underestimate the frequency of tumorigenic cells. In cancers with rapid genetic change, reversible changes in cell states, or biological variability among patients, the stem cell model may not be readily testable.
Nature Structural & Molecular Biology | 2009
John P. Hagan; Elena Piskounova; Richard I. Gregory
Lin28 and Lin28B, two developmentally regulated RNA-binding proteins and likely proto-oncogenes, selectively inhibit the maturation of let-7 family microRNAs (miRNAs) in embryonic stem cells and certain cancer cell lines. Moreover, let-7 precursors (pre–let-7) were previously found to be terminally uridylated in a Lin28-dependent fashion. Here we identify Zcchc11 (zinc finger, CCHC domain containing 11) as the 3′ terminal uridylyl transferase (TUTase) responsible for Lin28-mediated pre–let-7 uridylation and subsequent blockade of let-7 processing in mouse embryonic stem cells. We demonstrate that Zcchc11 activity is UTP-dependent, selective for let-7 and recruited by Lin28. Furthermore, knockdown of either Zcchc11 or Lin28, or overexpression of a catalytically inactive TUTase, relieves the selective inhibition of let-7 processing and leads to the accumulation of mature let-7 miRNAs and repression of let-7 target reporter genes. Our results establish a role for Zcchc11-catalyzed pre–let-7 uridylation in the control of miRNA biogenesis.
Cell | 2011
Elena Piskounova; Christos Polytarchou; James E. Thornton; Robert J. LaPierre; Charalabos Pothoulakis; John P. Hagan; Dimitrios Iliopoulos; Richard I. Gregory
Lin28A and Lin28B selectively block the expression of let-7 microRNAs and function as oncogenes in a variety of human cancers. Lin28A recruits a TUTase (Zcchc11/TUT4) to let-7 precursors to block processing by Dicer in the cell cytoplasm. Here we find that unlike Lin28A, Lin28B represses let-7 processing through a Zcchc11-independent mechanism. Lin28B functions in the nucleus by sequestering primary let-7 transcripts and inhibiting their processing by the Microprocessor. The inhibitory effects of Zcchc11 depletion on the tumorigenic capacity and metastatic potential of human cancer cells and xenografts are restricted to Lin28A-expressing tumors. Furthermore, the majority of human colon and breast tumors analyzed exclusively express either Lin28A or Lin28B. Lin28A is expressed in HER2-overexpressing breast tumors, whereas Lin28B expression characterizes triple-negative breast tumors. Overall our results illuminate the distinct mechanisms by which Lin28A and Lin28B function and have implications for the development of new strategies for cancer therapy.
Journal of Biological Chemistry | 2008
Elena Piskounova; Srinivas R. Viswanathan; Maja Janas; Robert J. LaPierre; George Q. Daley; Piotr Sliz; Richard I. Gregory
The developmentally regulated RNA-binding protein Lin28 blocks processing of let-7 family microRNAs (miRNAs) in embryonic cells. The molecular basis for this selective miRNA processing block is unknown. Here we find that Lin28 selectively binds the terminal loop region of let-7 precursors in vitro and that the loop mediates miRNA processing inhibition in vivo. Additionally, we identify the domains of Lin28 required for this inhibition. These findings establish a regulatory role for the terminal loop of precursors in miRNA maturation and provide insight into the mechanism by which Lin28 negatively regulates let-7 processing.
Nature | 2015
Elena Piskounova; Michalis Agathocleous; Malea M. Murphy; Zeping Hu; Sara E. Huddlestun; Zhiyu Zhao; A. Marilyn Leitch; Timothy M. Johnson; Ralph J. DeBerardinis; Sean J. Morrison
Solid cancer cells commonly enter the blood and disseminate systemically, but are highly inefficient at forming distant metastases for poorly understood reasons. Here we studied human melanomas that differed in their metastasis histories in patients and in their capacity to metastasize in NOD-SCID-Il2rg−/− (NSG) mice. We show that melanomas had high frequencies of cells that formed subcutaneous tumours, but much lower percentages of cells that formed tumours after intravenous or intrasplenic transplantation, particularly among inefficiently metastasizing melanomas. Melanoma cells in the blood and visceral organs experienced oxidative stress not observed in established subcutaneous tumours. Successfully metastasizing melanomas underwent reversible metabolic changes during metastasis that increased their capacity to withstand oxidative stress, including increased dependence on NADPH-generating enzymes in the folate pathway. Antioxidants promoted distant metastasis in NSG mice. Folate pathway inhibition using low-dose methotrexate, ALDH1L2 knockdown, or MTHFD1 knockdown inhibited distant metastasis without significantly affecting the growth of subcutaneous tumours in the same mice. Oxidative stress thus limits distant metastasis by melanoma cells in vivo.
Nature | 2017
Michalis Agathocleous; Corbin E. Meacham; Rebecca J. Burgess; Elena Piskounova; Zhiyu Zhao; Genevieve M. Crane; Brianna L. Cowin; Emily Bruner; Malea M. Murphy; Weina Chen; Gerald J. Spangrude; Zeping Hu; Ralph J. DeBerardinis; Sean J. Morrison
Stem-cell fate can be influenced by metabolite levels in culture, but it is not known whether physiological variations in metabolite levels in normal tissues regulate stem-cell function in vivo. Here we describe a metabolomics method for the analysis of rare cell populations isolated directly from tissues and use it to compare mouse haematopoietic stem cells (HSCs) to restricted haematopoietic progenitors. Each haematopoietic cell type had a distinct metabolic signature. Human and mouse HSCs had unusually high levels of ascorbate, which decreased with differentiation. Systemic ascorbate depletion in mice increased HSC frequency and function, in part by reducing the function of Tet2, a dioxygenase tumour suppressor. Ascorbate depletion cooperated with Flt3 internal tandem duplication (Flt3ITD) leukaemic mutations to accelerate leukaemogenesis, through cell-autonomous and possibly non-cell-autonomous mechanisms, in a manner that was reversed by dietary ascorbate. Ascorbate acted cell-autonomously to negatively regulate HSC function and myelopoiesis through Tet2-dependent and Tet2-independent mechanisms. Ascorbate therefore accumulates within HSCs to promote Tet activity in vivo, limiting HSC frequency and suppressing leukaemogenesis.
Science Translational Medicine | 2012
Elsa Quintana; Elena Piskounova; Mark Shackleton; Ugur Eskiocak; Douglas R. Fullen; Timothy M. Johnson; Sean J. Morrison
The ability of melanomas to produce circulating tumor cells and to metastasize in immunocompromised mice correlates with their ability to form distant metastases in patients. Melanomas in Miniature No two patients are exactly alike, so studying cancer biology in humans is complicated. There is no way to standardize experimental conditions or to analyze tumor biology in isolation. To overcome these difficulties, researchers use model animals such as mice, but these are never a perfect model of human physiology. For example, the process of cancer metastasis in mice frequently does not reflect findings in human patients. Some metastatic human cancers do not grow well in mice or do not metastasize. Now, Quintana et al. have developed a new mouse model of melanoma that provides a more faithful reproduction of human tumor metastasis and offers insights into the biology of circulating tumor cells. Quintana and colleagues used highly immunosuppressed mice to implant tumors from patients with stage III melanomas—those that have spread locally (typically to lymph nodes), but not beyond. All of the patients’ tumors were successfully implanted in this mouse model, but not all metastasized. Pathological analysis and bioluminescence imaging demonstrated that the spread of melanoma in the mouse model correlated with eventual spread of the disease in human patients. The same tumors that would later metastasize and kill their human hosts also metastasized widely in the mice. Conversely, melanomas that did not spread after surgical removal of the parent tumors from patients also metastasized slowly or inefficiently in animals, even after repeated passages of tumor cells through several generations of mice. To explain this phenomenon, the authors searched for human cancer cells in the blood of tumor-bearing mice and found a correlation there as well—the mice whose tumors metastasized efficiently had easily detectable tumor cells in their bloodstream, whereas the mice with poorly metastatic tumors did not. In this study, tumors were removed from their normal microenvironment and transplanted into mice; thus, this protocol permits only a partial view of the metastatic process. The new mouse model can be used to study intrinsic factors in cancer cells that contribute to metastasis but not immune factors or other patient-specific characteristics that may contribute to survival. Nevertheless, this report nicely demonstrates that at least some of the key factors that regulate melanoma metastasis are intrinsic to the tumors. The new mouse model will allow the characterization of metastatic processes and possibly point to markers that predict metastasis or therapeutic targets for human melanoma interventions. Studies of human cancer metastasis have been limited by a lack of experimental assays in which cancer cells from patients metastasize in vivo in a way that correlates with clinical outcome. This makes it impossible to study intrinsic differences in the metastatic properties of cancers from different patients. We recently developed an assay in which human melanomas readily engraft in nonobese diabetic/severe combined immunodeficient interleukin-2 receptor-γ chain null (NSG) mice. We show that melanomas from 25 patients exhibited reproducible differences in the rate of spontaneous metastasis after transplantation into NSG mice and that these differences correlated with clinical outcome in the patients. Stage IIIB/C melanomas that formed distant metastases within 22 months in patients also formed tumors that metastasized widely in NSG mice, whereas stage IIIB/C melanomas that did not form distant metastases within 22 to 50 months in patients metastasized more slowly in NSG mice. These differences in the efficiency of metastasis correlated with the presence of circulating melanoma cells in the blood of NSG mice, suggesting that the rate of entry into the blood is one factor that limits the rate of metastasis. The study of NSG mice can therefore yield information about the metastasis of human melanomas in vivo, in this case revealing intrinsic differences among stage III melanomas in their ability to circulate/survive in the blood and to metastasize.
Hormone Research in Paediatrics | 2012
Acácio P. Silveira-Neto; Letícia F. Leal; Amy B. Emerman; Katherine D. Henderson; Elena Piskounova; Brian E. Henderson; Richard I. Gregory; Leticia Ferreira Gontijo Silveira; Joel N. Hirschhorn; Thutrang T. Nguyen; Daiane Beneduzzi; Cintia Tusset; Ana Claudia S. Reis; Vinicius Nahime Brito; Berenice B. Mendonca; Mark R. Palmert; Sonir R. Antonini; Ana Claudia Latronico
Aim: To investigate LIN28B gene variants in children with idiopathic central precocious puberty (CPP). Patients and Methods: We studied 178 Brazilian children with CPP (171 girls, 16.8% familial cases). A large multiethnic group (1,599 subjects; Multiethnic Cohort, MEC) was used as control. DNA analysis and biochemical in vitro studies were performed. Results: A heterozygous LIN28B variant, p.H199R, was identified in a girl who developed CPP at 5.2 years. This variant was absent in 310 Brazilian control individuals, but it was found in the same allele frequency in women from the MEC cohort, independent of the age of menarche. Functional studies revealed that when ectopically expressed in cells, the mutant protein was capable of binding pre-let-7 microRNA and inhibiting let-7 expression to the same extent as wild-type Lin28B protein. Other rare LIN28B variants (p.P173P, c.198+ 32_33delCT, g.9575731A>C and c.-11C>T) were identified in CPP patients and controls. Therefore, no functional mutation was identified. Conclusion: In vitro studies revealed that the rare LIN28B p.H199R variant identified in a girl with CPP does not affect the Lin28B function in the regulation of let-7 expression. Although LIN28B SNPs were associated with normal pubertal timing, rare variations in this gene do not seem to be commonly involved in the molecular pathogenesis of CPP.
Cold Spring Harbor Symposia on Quantitative Biology | 2016
Jennifer G. Gill; Elena Piskounova; Sean J. Morrison
Reactive oxygen species (ROS) are highly reactive molecules that arise from a number of cellular sources, including oxidative metabolism in mitochondria. At low levels they can be advantageous to cells, activating signaling pathways that promote proliferation or survival. At higher levels, ROS can damage or kill cells by oxidizing proteins, lipids, and nucleic acids. It was hypothesized that antioxidants might benefit high-risk patients by reducing the rate of ROS-induced mutations and delaying cancer initiation. However, dietary supplementation with antioxidants has generally proven ineffective or detrimental in clinical trials. High ROS levels limit cancer cell survival during certain windows of cancer initiation and progression. During these periods, dietary supplementation with antioxidants may promote cancer cell survival and cancer progression. This raises the possibility that rather than treating cancer patients with antioxidants, they should be treated with pro-oxidants that exacerbate oxidative stress or block metabolic adaptations that confer oxidative stress resistance.
Molecular Cancer Research | 2016
Elena Piskounova; Michalis Agathocleous; Ralph J. DeBerardinis; Sean J. Morrison
Solid cancer cells commonly enter the blood and disseminate systemically but are highly inefficient at forming distant metastases for poorly understood reasons. We studied human melanomas that differed in their metastasis histories in patients and in their capacity to metastasize in NSG mice. All melanomas had high frequencies of cells that formed subcutaneous tumors, but much lower percentages of cells that formed tumors after intravenous or intrasplenic transplantation, particularly among inefficient metastasizers. Melanoma cells in the blood and visceral organs experienced oxidative stress not observed in established subcutaneous tumors. Successfully metastasizing melanomas underwent reversible metabolic changes during metastasis that increased their capacity to withstand oxidative stress, including increased dependence upon NADPH-generating enzymes in the folate pathway. Anti-oxidants promoted distant metastasis in NSG mice. Folate pathway inhibition using low-dose methotrexate, ALDH1L2 knockdown, or MTHFD1 knockdown inhibited distant metastasis without significantly affecting the growth of subcutaneous tumors in the same mice. Oxidative stress thus limits distant metastasis by melanoma cells in vivo. Citation Format: Elena Piskounova, Michalis Agathocleous, Ralph J. DeBerardinis, Sean J. Morrison. Oxidative stress inhibits distant metastasis by human melanoma cells. [abstract]. In: Proceedings of the AACR Special Conference: Developmental Biology and Cancer; Nov 30-Dec 3, 2015; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(4_Suppl):Abstract nr IA08.